Lead Product(s) : SAR442501
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects
Details : SAR442501 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteochondrodysplasias.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : SAR442501
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioRestorative Gets FDA Clearance for BRTX-100 Phase 2 Trial
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic cervical discogenic pain.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TTAX03
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TTAX03 for the Treatment of Lumbosacral Facet Joint Pain
Details : TTAX03 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Facet Joint Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : TTAX03
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG-C
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TG-C is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intervertebral Disc Degeneration.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : TG-C
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactic Acid
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Cromsource | Antaros Medical | Viedoc
Deal Size : Inapplicable
Deal Type : Inapplicable
STA363 in the Treatment of Lumbar Disc Herniation
Details : Lactic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lumbar Disc Herniation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Lactic Acid
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Cromsource | Antaros Medical | Viedoc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture
Details : Diclofenac is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fractures, Bone.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Diclofenac
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HST003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HST003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Knee Articular Cartilage Disorder.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : HST003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wrist Fractures.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Dexamethasone
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenomir
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow
Details : Tenomir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tennis Elbow.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Tenomir
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lumbar Discogenic Pain.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 26, 2019
Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable